|NASDAQ: ENLV||Healthcare / Biotechnology / Israel|
|3.57||-0.0900||-2.46%||Vol 28.02K||1Y Perf -31.46%|
|Mar 24th, 2023 15:08 DELAYED|
|- -||- -%|
|Target Price||15.00||Analyst Rating||Strong Buy 1.00|
|Potential %||320.17||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||2.87||Earnings Rating||—|
|Market Cap||48.06M||Earnings Date||5th May 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th May 2023|
|Estimated EPS Next Report||-0.38|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||12.97K|
|Avg. Monthly Volume||16.96K|
|Avg. Quarterly Volume||27.70K|
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) stock closed at 3.57 per share at the end of the most recent trading day (a -2.46% change compared to the prior day closing price) with a volume of 28.02K shares and market capitalization of 48.06M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 36 people. Enlivex Therapeutics Ltd. CEO is Oren Hershkovitz.
The one-year performance of Enlivex Therapeutics Ltd. stock is -31.46%, while year-to-date (YTD) performance is -9.33%. ENLV stock has a five-year performance of %. Its 52-week range is between 3.42 and 8.64, which gives ENLV stock a 52-week price range ratio of 2.87%
Enlivex Therapeutics Ltd. currently has a PE ratio of -2.70, a price-to-book (PB) ratio of 1.24, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -36.78%, a ROC of -35.35% and a ROE of -41.49%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Enlivex Therapeutics Ltd., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.38 for the next earnings report. Enlivex Therapeutics Ltd.’s next earnings report date is 05th May 2023.
The consensus rating of Wall Street analysts for Enlivex Therapeutics Ltd. is Strong Buy (1), with a target price of $15, which is +320.17% compared to the current price. The earnings rating for Enlivex Therapeutics Ltd. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Enlivex Therapeutics Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Enlivex Therapeutics Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 18.23, ATR14 : 0.15, CCI20 : -53.29, Chaikin Money Flow : -0.16, MACD : -0.13, Money Flow Index : 27.90, ROC : -6.79, RSI : 34.53, STOCH (14,3) : 26.32, STOCH RSI : 0.56, UO : 42.06, Williams %R : -73.68), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Enlivex Therapeutics Ltd. in the last 12-months were:
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Strong Buy|
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
CEO: Oren Hershkovitz
Telephone: +972 26208072
Address: 14 Einstein Street, Nes Ziona 7403618, , IL
Number of employees: 36
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.